|
Veliparib (ABT-888)〔("ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models" ) May 2007〕 is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It inhibits both PARP1 and PARP2.〔http://www.cancer.gov/drugdictionary/?CdrID=496464〕〔("ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models" ), 2007〕 ==Clinical trials== Numerous phase I clinical trials are in progress.〔http://clinicaltrialsfeeds.org/clinical-trials/results/term=Drug:+ABT-888〕 A phase I/II clinical trial for use with/out doxorubicin (for Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma) started in 2008 and is due to complete in 2010.〔("ABT-888 and Cyclophosphamide With Versus Without Doxorubicin in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma" )〕 Results (inc MTD) with topotecan. A phase II clinical trial for metastatic melanoma has started recruiting.〔("A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma" )〕 Due to end Dec 2011. A phase II clinical trial for metastatic breast cancer has started recruiting.〔("ABT-888 and Temozolomide for Metastatic Breast Cancer" )〕 Due to end Nov 2011. A phase II clinical trial for add-on to Radiation Therapy for Patients with Brain Metastases from Non-Small Cell Lung Cancer. It was included in the I-SPY2 breast cancer trial,〔("Breast cancer study aims to speed drugs, cooperation" ), March 2010〕 and there are encouraging data from that study 〔http://www.centerwatch.com/news-online/article/5737/new-presurgery-combination-therapy-for-triple-negative-breast-cancer〕 A phase I clinical trial for prostate cancer in men who carry the BRCA mutation is underway and is now recruiting (as of May 2013).〔("Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy. Clinical Trial NCT00892736" )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Veliparib」の詳細全文を読む スポンサード リンク
|